Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Toll Like Receptor 8 (CD288 or TLR8) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Toll Like Receptor 8 (CD288 or TLR8) Products under Development by Stage of Development | 8 | 1 |
| Toll Like Receptor 8 (CD288 or TLR8) Products under Development by Therapy Area | 9 | 1 |
| Toll Like Receptor 8 (CD288 or TLR8) Products under Development by Indication | 10 | 2 |
| Toll Like Receptor 8 (CD288 or TLR8) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Toll Like Receptor 8 (CD288 or TLR8) Products under Development by Companies | 14 | 3 |
| Toll Like Receptor 8 (CD288 or TLR8) Therapeutics Assessment | 17 | 7 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 2 |
| Assessment by Route of Administration | 20 | 2 |
| Assessment by Molecule Type | 22 | 2 |
| Toll Like Receptor 8 (CD288 or TLR8) Companies Involved in Therapeutics Development | 24 | 9 |
| 3M Drug Delivery Systems | 24 | 1 |
| Foamix Pharmaceuticals Ltd. | 25 | 1 |
| Folia Biotech Inc. | 26 | 1 |
| Galderma S.A. | 27 | 1 |
| Idera Pharmaceuticals, Inc. | 28 | 1 |
| MedImmune, LLC | 29 | 1 |
| Merck &Co., Inc. | 30 | 1 |
| Resolve Therapeutics, LLC | 31 | 1 |
| VentiRx Pharmaceuticals, Inc. | 32 | 1 |
| Toll Like Receptor 8 (CD288 or TLR8) Drug Profiles | 33 | 26 |
| 854-A Drug Profile | 33 | 1 |
| Drug 1 to Agonize TLR7 and TLR8 for Oncology Drug Profile | 34 | 1 |
| Drug 2 to Agonize TLR7 and TLR8 for Oncology Drug Profile | 35 | 1 |
| Drug to Agonize TLR7 and TLR8 for Oncology Drug Profile | 36 | 1 |
| imiquimod Drug Profile | 37 | 1 |
| IMO-8400 Drug Profile | 38 | 6 |
| IMO-9200 Drug Profile | 44 | 2 |
| JB-6121 Drug Profile | 46 | 1 |
| leishmaniasis vaccine Drug Profile | 47 | 1 |
| MEDI-9197 Drug Profile | 48 | 1 |
| motolimod Drug Profile | 49 | 4 |
| resiquimod Drug Profile | 53 | 1 |
| RSLV-132 Drug Profile | 54 | 2 |
| Small Molecules to Agonize TLR7/8/9 for Cancer, Alzheimer's Disease and Infectious Disease Drug Profile | 56 | 1 |
| VTX-1463 Drug Profile | 57 | 1 |
| VTX-294 Drug Profile | 58 | 1 |
| Toll Like Receptor 8 (CD288 or TLR8) Dormant Projects | 59 | 1 |
| Toll Like Receptor 8 (CD288 or TLR8) Discontinued Products | 60 | 1 |
| Toll Like Receptor 8 (CD288 or TLR8) Featured News &Press Releases | 61 | 12 |
| May 26, 2016: Resolve To Present Data On Lupus Studies At International Rheumatology Conference | 61 | 1 |
| Feb 10, 2016: Resolve Announces Positive Clinical Data From RSLV-132 Lupus Study | 61 | 1 |
| Dec 05, 2015: Idera Pharmaceuticals Reports Positive Data From Ongoing Phase 1/2 Clinical Trial of IMO-8400 in Patients With Waldenstrom s Macroglobulinemia | 62 | 1 |
| Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis | 63 | 1 |
| Nov 05, 2015: Idera Pharmaceuticals to Present Phase 1/2 IMO-8400 Clinical Data in Waldenstrom s Macroglobulinemia at the 2015 American Society of Hematology Annual Meeting | 64 | 1 |
| May 18, 2015: Idera Pharmaceuticals Provides Development Update on IMO-9200, an Antagonist of Toll-like Receptors | 64 | 2 |
| Apr 27, 2015: VentiRx Pharmaceuticals Granted Orphan Drug Designation in the European Union For Motolimod in the Treatment of Ovarian Cancer | 66 | 1 |
| Apr 01, 2015: Idera Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse Large B-Cell Lymphoma | 66 | 1 |
| Dec 30, 2014: Idera Provides Key Updates on Clinical Development of IMO-8400 for Treatment of Waldenstrom's Macroglobulinemia | 67 | 1 |
| Dec 08, 2014: Idera Pharmaceuticals Presents Data Supporting IMO-8400 as Novel Therapy for Genetically Defined Forms of B-Cell Lymphoma at Annual ASH Meeting | 67 | 2 |
| Nov 06, 2014: Idera Pharmaceuticals Announces Upcoming Presentations of Data on IMO-8400 From Oncology Programs at Key Scientific Meetings | 69 | 1 |
| Oct 14, 2014: Idera Pharmaceuticals Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200 | 70 | 1 |
| Sep 03, 2014: Ludwig Cancer Research And Cancer Research Institute Collaborate On Evaluation Of Ventirx's Investigational Immunotherapy | 70 | 1 |
| Sep 02, 2014: VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer | 71 | 1 |
| Aug 08, 2014: Idera Pharmaceuticals and The Myositis Association Join Forces to Advance the Clinical Development of a Novel TLR Antagonist, IMO-8400, for the Treatment of Myositis | 72 | 1 |
| Appendix | 73 | 2 |
| Methodology | 73 | 1 |
| Coverage | 73 | 1 |
| Secondary Research | 73 | 1 |
| Primary Research | 73 | 1 |
| Expert Panel Validation | 73 | 1 |
| Contact Us | 73 | 1 |
| Disclaimer | 74 | 1 |